Search the site
Lauren Daly
Associate
Lauren is an Associate at Sprigings IP. Lauren graduated from the Juris Doctor program at Queen’s University. Prior to law school, Lauren received a Bachelor of Science in Biology from Carleton University. During law school, Lauren competed in the Harold G. Fox Intellectual Property Moot, where her team won the Harold G. Fox Cup for best mooting team, and Lauren received the runner-up Daniel F. Sim best oral advocate award. In March 2024, her team competed at the Oxford University International Intellectual Property Moot and won Best New Team. She also worked with the Kingston Community Legal Clinic to assist on a Charter case for unhoused encampment residents in Kingston and was an executive on the Queen’s Law Cancer Society and the Queen’s Law International Law Club.
Education
- B.Sc., Carleton University
- J.D., Queen’s University
Bar Admission
- Ontario, 2025
%20(1).jpg)
My recent cases
Proceeding for patent impeachment relating to pembrolizumab.
Application for a declaration of non‑infringement regarding pembrolizumab.
Application for a declaration of non‑infringement regarding pembrolizumab.
Application under subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations regarding apalutamide.
Action under section 8.2 of the Patented Medicines (Notice of Compliance) Regulations regarding apalutamide.
Application under subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations regarding apalutamide.
Application under subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations regarding aflibercept.
Action under section 8.2 of the Patented Medicines (Notice of Compliance) Regulations regarding aflibercept.
Action under section 8.2 of the Patented Medicines (Notice of Compliance) Regulations regarding aflibercept.
Action under section 8.2 of the Patented Medicines (Notice of Compliance) Regulations regarding aflibercept.
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,652,442 and 2,771,403 (lenvatinib).
More people
.jpg)
.jpg)
.jpg)
.jpeg)
.jpg)
.jpg)
.jpg)
